Matthew Loudon, PA
Medical · Wasilla, AKNPI 1922498781
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,798 of the $6,144 with a category attached, or 61.8%. 25 manufacturers reported payments, led by Insulet Corporation at 43.3% of the total. 2025 is the largest year on record at $3,470, 6.3 times the $549 reported in 2021. Among medical clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $35.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$3K
- Sanofi-aventis U.S. LLC$531
- Abbott$469
- AstraZeneca$391
- Lilly USA, LLC$376
- Amgen$364
- plus $1K from 19 others
What the payments were for
- Travel & lodging$2,27037%
- Food & beverage$3,79862%
- Education$761%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 15 | $2,662 |
| Sanofi-aventis U.S. LLC | 17 | $531 |
| Abbott | 17 | $469 |
| AstraZeneca | 19 | $391 |
| Lilly USA, LLC | 21 | $376 |
| Amgen | 16 | $364 |
| Novo Nordisk | 18 | $363 |
| Novartis | 8 | $175 |
| Xeris Pharmaceuticals, Inc. | 5 | $101 |
| Medtronic | 4 | $92 |
| Merck | 5 | $75 |
| Tandem Diabetes Care, Inc. | 5 | $74 |
| AbbVie | 4 | $68 |
| Bayer | 3 | $56 |
| Dexcom, Inc. | 2 | $46 |
| Amarin Pharma, Inc. | 2 | $42 |
| Boehringer Ingelheim | 2 | $41 |
| IBSA Pharma Inc. | 2 | $36 |
| Corcept Therapeutics | 1 | $35 |
| Nevro Corp. | 1 | $34 |
| Blueprint Medicines Corporation | 1 | $33 |
| Sun Pharmaceutical Industries Inc. | 1 | $27 |
| BETA Bionics, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$2,407
- FREESTYLE LIBRE 3$177
- TZIELD$126
How this compares
$6,144 in reported general payments places this provider in the 95th percentile of 140 medical providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 299 | $551,373 |
| FarxigaDapagliflozin Propanediol | 180 | $258,879 |
| Tresiba Flextouch U-200Insulin Degludec | 133 | $247,888 |
| TrulicityDulaglutide | 116 | $204,146 |
| Tresiba Flextouch U-100Insulin Degludec | 150 | $135,977 |
| JardianceEmpagliflozin | 93 | $131,684 |
| Xigduo XrDapaglifloz Propaned/Metformin | 99 | $128,941 |
| MounjaroTirzepatide | 72 | $108,410 |
| JanuviaSitagliptin Phosphate | 62 | $88,268 |
| RybelsusSemaglutide | 35 | $79,749 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 23 | $58,672 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 47 | $55,370 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 25 | $51,462 |
| Humalog Kwikpen U-200Insulin Lispro | 20 | $46,472 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 12 | $45,218 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $363 | $689,794357 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $376 | $316,563202 claims |
| AstraZenecaFarxiga | $391 | $258,879180 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $41 | $150,818109 claims |
| MerckJanuvia, Janumet Xr | $75 | $143,638109 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $531 | $42,01220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 140 medical providers in Alaska.
Other medical in Wasilla
- Richard BlakeWasilla$19K
- Kathryn AlbertWasilla$5K
- Karen ClementWasilla$5K
- Ksenia SokolovaWasilla$4K
- Katelyn StearnsWasilla$3K
- John MooreWasilla$2K
- Savanna SimmermanWasilla$1K
- Jessica van WulvenWasilla$1K
- Danielle McKinneyWasilla$1K
- Nathan FitzgeraldWasilla$761
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.